Polaris Quantum Biotech (PolarisQB) has released a comparative study indicating that its Quantum-Aided Drug Design (QuADD) platform, powered by D-Wave Quantum Inc.’s annealing technology, significantly outperforms classical Generative AI in lead identification for drug discovery. The study, currently a preprint on ChemRxiv, compared QuADD to the Bond and Interaction generating Diffusion model (BInD), a representative AI-based diffusion algorithm. The findings suggest that quantum annealing can reduce the timeline for selecting pre-clinical molecular candidates from months to hours while delivering higher-quality results.
Watch here.